NAMPT与恶性肿瘤的进展  

The research progress on NAMPT in malignant tumors

作　　者：李广浩[1] 张玉宝[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院肝胆胰外科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2016年第2期158-161,共4页Practical Oncology Journal

摘　　要：烟酰胺磷酸核糖转移酶（Nicotinamidephos phoribosyltransferase，NAMPT）是烟酰胺腺嘌呤二核苷酸（Nicotinamide adenine dinucleotide，NAD）补救合成途径的关键限速酶，并参与调节细胞的代谢、增殖、凋亡等生物学过程。近年来，研究发现NAMPT在多种恶性肿瘤中表达水平升高，并与恶性肿瘤的发生、发展及治疗关系密切。NAMPT在恶性肿瘤中作用机制的研究以及NAMPT抑制剂的研究为恶性肿瘤的治疗带来了新的希望和前景。本文将NAMPT在恶性肿瘤中的研究现状做一简要综述。Nicotinamide phosphoribosyhransferase（NAMPT） is the rate -limiting enzyme that catalyzes the first step in Nicotinamide adenine dinucleotide（NAD） biosynthesis and regulates biological processes such as metab- olism, growth and apoptosis of ceils. In the past few years, a large number of studies have found that expression level of NAMPT is increased in a variety of malignancies, which is associated with the progression and treatment of malig- nant tumors. The research of the mechanism of NAMPT in malignant tumors and molecule inhibitors of the NAMPT have brought new hope and prospect for the treatment of malignant tumors. This article makes a brief review of NAMPT research status in malignant tumors.

关 键 词：NAMPT 恶性肿瘤 进展 治疗 

分 类 号：R73[医药卫生—肿瘤]